echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > The nmpa approved 51 anti epidemic material enterprises, MSD insomnia therapy, and approved

    The nmpa approved 51 anti epidemic material enterprises, MSD insomnia therapy, and approved

    • Last Update: 2020-02-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    (2020/02/17) novel coronavirus pneumonia inhibitor PDE5 was approved by the State Administration of drug supervision and quarantine in China What are the 24 clinical trials for 116 days in the new medical care organization? How to overcome the problem of drug resistance? 2020asco SITC announced the new plan; Qilu pharmaceutical "pregabalin capsule" will be approved as the first to pass the consistency evaluation Stardust is a randomized, multicenter, interventional phase 3B study Pregabalin, trade name Lyrica, is a GABA analogue developed by Pfizer Attack frequency significantly reduced! From January 20 to February 12, each province successively made a first-class response, and a total of 51 Enterprises and 75 registration applications for epidemic prevention materials were approved Sema4D, also known as CD100, is highly expressed in many human tumor tissues and plays an important role in angiogenesis, tumor invasion and metastasis These clinical trials involve both western medicine and traditional Chinese medicine.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.